Genomics Vision 2020

Due to the COVID-19 situation, the conference has
been postponed to a later date, to be advised.
We thank you for your understanding.

Welcome Message

On June 26, 2000, then president of the United States of America, Bill Clinton, announced the completion of the first draft of human genome sequence – the very blueprint of life. The Human Genome Project (HGP) was the international, collaborative research program whose goal was the complete mapping and understanding of all the genes of human beings. The completion and release of the human draft genome marked the new era of rapid development in genomic science. Such a rapid development has not only led to the dramatic reduction of the cost of sequencing a human genome from 100M USD to less than 1000 USD, but also the wide adoption and application of genomic technologies in diverse fields of scientific research and medicine.

That very same year, Singapore also launched its very own national initiative on genomics and established the Genome Institute of Singapore (GIS). With a vision to improve human health and public prosperity through genomic sciences, GIS has pursued the integration of genomic technologies, genetics, computation and biology in diverse research areas, such as population genetics, cancer genomics, infectious diseases, and regenerative medicine.

By collaborating closely with its clinical partners, GIS has also tried hard to translate its scientific discoveries and research strength to economic and clinical benefits. Through its research and translational efforts, GIS has helped to place Singapore on the global map in genomic research and contributed towards Singapore’s reputation and branding as a leading biomedical research hub in Asia.

The year 2020 marks GIS’ 20th anniversary. To celebrate this milestone, we are organising a conference, Genomics vision 2020, to showcases the achievements and progresses of genomic science by bringing together leading experts from the various fields of genomics, as well as spur new discussions and collaborations across the disciplinary boundaries for future explorations. The conference will have scientific sessions on Precision Medicine & Population Genomics, Frontiers in Genomics, Clinical Genomics, and Microbial Genomics, as well as a Public Forum on Genomics.

On behalf of the GIS and the Genomics Vision 2020 organising committee, we would like to welcome all of you to this conference, and assure you enjoyable and fruitful days of scientific exchanges!

Organising Committee

LIU Jian Jun
Roger FOO
KHOR Chiea Chuen
Swaine CHEN
LI Jingmei
TAM Wai Leong
Madeline SHEE
Winnie LIM
Keryn CHUA

About GIS

The Genome Institute of Singapore (GIS) is an institute of the Agency for Science, Technology and Research (A*STAR). It has a global vision that seeks to use genomic sciences to achieve extraordinary improvements in human health and public prosperity. Established in 2000 as a centre for genomic discovery, the GIS will pursue the integration of technology, genetics and biology towards academic, economic and societal impact.

The key research areas at the GIS include Human Genetics, Infectious Diseases, Cancer Therapeutics and Stratified Oncology, Stem Cell and Regenerative Biology, Cancer Stem Cell Biology, Computational and Systems Biology, and Translational Research.

The genomics infrastructure at the GIS is utilised to train new scientific talent, to function as a bridge for academic and industrial research, and to explore scientific questions of high impact.

For more information about GIS, please visit

About A*STAR

The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit society.

As aScience and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by contributing to societal benefits such as improving outcomes in healthcare, urban living, and sustainability.

We play a key role in nurturing and developing a diversity of talent and leaders in our Agency and research entities, the wider research community and industry. A*STAR’s R&D activities span biomedical sciences and physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis.

For ongoing news, visit